CEL-SCI says Oral Oncology accepts Multikine Phase 3 data showing survival benefit in low PD-L1 oral cancer patients

• CEL-SCI reported a leading oncology journal accepted for publication new Phase 3 Multikine data in head and neck cancer.
• Results were previously generated in the completed trial; detailed findings will be disclosed when the paper is published.
• In a predefined underserved subgroup, Multikine paired with standard care was associated with better long-term survival than standard care alone.
• The company is preparing to start enrollment in a 212-patient confirmatory registration study to validate the survival benefit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607300831BIZWIRE_USPR_____20260730_BW371018) on July 30, 2026, and is solely responsible for the information contained therein.